Frailty in Parkinson's disease and its association with early dementia: A longitudinal study


Por: Borda M.G., Pérez-Zepeda M.U., Jaramillo-Jimenez A., Chaudhuri K.R., Tovar-Rios D.A., Wallace L., Batzu L., Rockwood K., Tysnes O.-B., Aarsland D., Alves G.

Publicada: 1 ene 2022
Resumen:
Introduction: Frailty is recognized as a clinical condition associated with increased vulnerability for developing negative health outcomes but has been little studied in patients with Parkinson's disease (PD). Here, we investigated the risk of frailty in de novo PD patients and its association with subsequent development of dementia. Methods: We conducted a three-year longitudinal population-based study of 192 drug-naive newly diagnosed PD patients and 172 controls (No-PD) matched for age, sex, and education. Frailty was measured using the frailty index (FI). Logistic regression models, adjusting for potential confounders, were conducted to assess the association between frailty at the time of PD diagnosis and the subsequent odds for developing PD dementia during follow-up. Results: The mean baseline FI score was higher in the PD (0.21 ± 0.10) than in the No-PD group (0.11 ± 0.07, p < 0.001). One-third of PD patients had high-FI (>0,25), compared to 5% in the no-PD group. Participants with PD had an increased risk to present frailty with an odds ratio (OR) of 6.68 (SE 2.70 IC 95% [3.15; 15.62], p-value <0.001) compared to the No-PD group. PD Participants with greater FI measured at baseline had increased odds of having dementia within three years of follow-up, after adjustment for age and sex (OR 2.91 SE 1.00 IC 95% [1.54; 5.99] p-value = 0.002). Conclusion: Frailty is common in people with newly diagnosed PD and associated with increased odds for subsequent development of dementia in a three-year follow-up. This study emphasizes the prognostic importance of frailty in PD from the earliest clinical stages. © 2022 The Authors

Filiaciones:
Borda M.G.:
 Centre for Age-Related Medicine (SESAM), Stavanger University Hospital. Stavanger, Norway

 Semillero de Neurociencias y Envejecimiento, Ageing Institute, Medical School, Pontificia Universidad Javeriana, Bogotá, Colombia

 Faculty of Health Sciences, University of Stavanger, Stavanger, Norway

Pérez-Zepeda M.U.:
 Semillero de Neurociencias y Envejecimiento, Ageing Institute, Medical School, Pontificia Universidad Javeriana, Bogotá, Colombia

 Geriatric Medicine Research, Dalhousie University, Nova Scotia Health Authority, Halifax, NS, Canada

 Geriatric Epidemiology Research Department, Instituto Nacional De Geriatría (INGER), Mexico City, Mexico

 Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Huixquilucan Edo. de México, Mexico

Jaramillo-Jimenez A.:
 Centre for Age-Related Medicine (SESAM), Stavanger University Hospital. Stavanger, Norway

 Faculty of Health Sciences, University of Stavanger, Stavanger, Norway

 Grupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellín, Colombia

Chaudhuri K.R.:
 Parkinson Foundation Centre of Excellence at King's College Hospital and Kings College, London, Denmark Hill, SE5 9RS, United Kingdom

 Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, LondonSE5 9RT, United Kingdom

Tovar-Rios D.A.:
 Centre for Age-Related Medicine (SESAM), Stavanger University Hospital. Stavanger, Norway

 Faculty of Health Sciences, University of Stavanger, Stavanger, Norway

 Grupo INFERIR, Facultad de Ingeniería, Universidad del Valle, Valle del Cauca, Santiago de Cali, Colombia

Wallace L.:
 Geriatric Medicine Research, Dalhousie University, Nova Scotia Health Authority, Halifax, NS, Canada

 Cambridge Public Health, University of Cambridge, Cambridge, United Kingdom

Batzu L.:
 Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, United Kingdom

Rockwood K.:
 Geriatric Medicine Research, Dalhousie University, Nova Scotia Health Authority, Halifax, NS, Canada

Tysnes O.-B.:
 Department of Neurology, Haukeland University Hospital, Bergen, Norway

Aarsland D.:
 Centre for Age-Related Medicine (SESAM), Stavanger University Hospital. Stavanger, Norway

 Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, United Kingdom

Alves G.:
 The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway

 Department of Neurology, Stavanger University Hospital, Stavanger, Norway

 Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway
ISSN: 13538020
Editorial
ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 99 Número:
Páginas: 51-57
WOS Id: 000808090200009
ID de PubMed: 35598420
imagen Hybrid Gold